Short DAPT Eligibility Calculator

Short DAPT Eligibility Calculator Explanation and Clinical Context This tool is designed for patients with acute coronary syndromes who have undergone percutaneous coronary intervention with contemporary drug eluting stents and are treated with dual antiplatelet therapy that combines aspirin and an oral P2Y12 inhibitor. The 2025 acute coronary syndromes guideline identifies a default strategy of about 12 months of dual antiplatelet therapy in patients who are not at high bleeding risk and emphasizes that shorter or longer durations should be tailored to the balance between bleeding and ischemic risk. Evidence from randomized trials such as MASTER DAPT and other studies of abbreviated dual antiplatelet strategies suggests that in patients at high bleeding risk who have completed about 1 month of dual antiplatelet therapy without recurrent ischemic events transition to single antiplatelet therapy can reduce clinically relevant bleeding without a clear excess of major adverse cardiovascular events.

The guideline therefore supports consideration of abbreviated regimens in carefully selected high bleeding risk patients particularly when coronary anatomy is not highly complex and when there has been no recurrent myocardial infarction stent thrombosis or unstable ischemia. This calculator uses a qualitative rule based approach that combines Academic Research Consortium high bleeding risk status completion of at least 1 month of dual antiplatelet therapy early bleeding tolerance and the presence or absence of ischemic and anatomic features that usually favor standard or longer duration dual antiplatelet therapy. The output categorizes the patient profile as favoring a short duration strategy suggesting that short dual antiplatelet therapy is possible but requires caution or favoring standard duration.

The result does not replace formal risk scores such as PRECISE DAPT or DAPT score and does not supersede local protocols. Coronary angiographic details multidisciplinary discussion and patient preference are essential in final decision making. Clinicians should also integrate the presence of a chronic indication for oral anticoagulant therapy which often favors earlier transition to a single antiplatelet agent together with anticoagulant therapy to limit bleeding risk.

Regular reassessment of bleeding and ischemic risk during follow up is important because these risks can change over time with new comorbid conditions procedures or events. Reference Rao SV O Donoghue ML Ruel M et al. 2025 guideline for the management of patients with acute coronary syndromes.

Journal of the American College of Cardiology. 2025 85 22 2135 2237. Valgimigli M Frigoli E Heg D et al.

Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk. New England Journal of Medicine. 2021 385 1643 1655.

Urban P Mehran R Colleran R et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation.

2019 140 240 261.